Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#1711 Survival Analysis of Combined Therapy with 177Lu-Octreotate and Somatostatin Analogues in Advanced Metastatic Neuroendocrine Tumours

Introduction: Although somatostatin analogues (SSA) and peptide receptor radionuclide therapy with 177Lu-octreotate (PRRT) are validated therapies in patients with advanced metastatic neuroendocrine tumours, it is still unclear if the combined therapy with PRRT and SSA can provide a prolonged survival compared to patients treated with PRRT alone.

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Yordanova A

Authors: Yordanova A, Wicharz M, Gonzalez-Carmona M, Strassburg C, Mayer K,

Keywords: PRRT, SSA, combined therapy, survival,

#921 Combined Therapy with RAD001 e BEZ235 Overcomes Resistance of PET Cells to mTOR Inhibition

Introduction: Since the PI3K/Akt/mTOR proliferation axis is often deregulated in PETs, the mTORC1 complex inhibitor Everolimus (RAD001) represents an effective treatment for PETs. However, RAD001 leads to a re-activation of PI3K activity and phosphorylation of Akt, which may promote resistance to the treatment. Thus, direct inhibition of PI3K may represent a novel potential target for PETs.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Passacantilli I, Capurso G, Archibugi L, Calabretta S, Delle Fave G,

Keywords: mTOR, PI3K, resistance,

#634 Merkel Cell Carcinoma in a Nine-Year-Old Girl

Introduction: Merkel cell carcinoma (MCC) of the skin is a rare neuroendocrine tumor characterized by its rapid growth and aggressive clinical behavior. MCC is a typical tumor of older age (average age is 65 years). In children and adolescents less than 20 years of age, it is extremely rare. Information regarding MCC in childhood can be found in the literature only in the form of individual case reports. Due to the rarity of MCC in the young population, any clinical studies or treatment recommendations in these patients are missing.

Conference: 10th Annual ENETSConcerence (2013)

Presenting Author: Bajciova V

Authors: Bajciova V, Kren L, Sterba J, Prasek J,

Keywords: Merkel cell carcinoma, pediatric age, rarity, effective treatment,